Our exceptional results for the third quarter demonstrate that Sanofi is on the right path.
We delivered remarkable sales growth and our commitment to breakthrough science is bearing fruit as we achieved key regulatory milestones for three of our priority medicines.
Paul Hudson
Chief Executive Officer, Sanofi
Company sales and business EPS*
€12,482m
€2.88
+9.0% (+19.7%)
+17.9% (+32.1%)
Q3 2022
Q3 2022
company sales **
business EPS **
Earnings per share
Growth rates are expressed at constant exchange rates (CER). Growth rates in parentheses are expressed on a reported basis.
Sales by geography
U S
€6,042m
Rest of
the World
Europe
€3,844m
€2,596m
For further information on Q3 2022 results
and definitions of financial indicators, please refer to the press release issued on October 28, 2022 at:
www.sanofi.com/en/investors
Sales by global business unit
€4,401m
€3,315m
Specialty Care
Vaccines
€3,495m
€1,271m
General Medicines
Consumer Healthcare
Social Impact
Delivering positive impact
on communities and the environment
Sanofi is advancing towards its Net Zero target by 2050.
Two carbon offsetting programs launched with EcoAct in Kenya:
Restoring 500 hectares
Distributing 18,250 energy-saving
of mangroves
biomass cookstoves
. Removes approx. 390 kt CO2e
. Avoids approx. 790 kt CO2e
. Improves water quality
. Prevents deforestation
and biodiversity
. Improves health and social conditions
. Creates jobs
of local rural families
@Sanofi @Sanofi @Sanofi @SanofiaventisTVen
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sanofi SA published this content on 28 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2022 05:32:08 UTC.
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
- pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases);
- human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas;
- consumer health products (12%).
At the end of 2023, the group had 54 production sites throughout the world.
Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
SANOFI 
